ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood-derived immune stem cells and establishes a novel, flexible, consistent, and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next, we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells, and macrophages. Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies.
Something looks off?